The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Open accessAbstract
UNLABELLED: Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 consecutive patients with advanced neuroendocrine tumors, we evaluated whether treatment with (177)Lu-labeled sst antagonists is feasible. METHODS: After injection of approximately 1 GBq of (177)Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2] ((177)Lu-DOTA-JR11) and (177)Lu-DOTATATE, 3-dimensional voxel dosimetry analysis based on SPECT/CT was performed. A higher tumor-to-organ dose ratio for (177)Lu-DOTA-JR11 than for (177)Lu-DOTATATE was the prerequisite for treatment with (177)Lu-DOTA-JR11. RESULTS: Reversible minor adverse effects of (177)Lu-DOTA-JR11 were observed. (177)Lu-DOTA-JR11 showed a 1.7-10.6 times higher tumor dose than (177)Lu-DOTATATE. At the same time, the tumor-to-kidney and tumor-to-bone marrow dose ratio was 1.1-7.2 times higher. All 4 patients were treated with (177)Lu-DOTA-JR11, resulting in partial remission in 2 patients, stable disease in 1 patient, and mixed response in the other patient. CONCLUSION: Treatment of neuroendocrine tumors with radiolabeled sst antagonists is clinically feasible and may have a significant impact on peptide receptor radionuclide therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Self-citationWild, D., Bomanji, J. B., Benkert, P., Maecke, H., Ell, P. J., Reubi, J. C., & Caplin, M. E. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111724 · Cited by 218
Self-citationFirst Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Behe, M., Brink, I., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., & Weber, W. A. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 183
Self-citationPeptide-receptor radionuclide therapy for endocrine tumors
van Essen, M., Krenning, E. P., Kam, B. L. R., de Jong, M., Valkema, R., & Kwekkeboom, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.105 · Cited by 173
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172
Self-citationCescato, R., Waser, B., Fani, M., & Reubi, J. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.095778 · Cited by 108
Self-citationMonoamine transporter availability in Parkinson’s disease patients with or without depression
Hesse, S., Meyer, P., Strecker, K., Barthel, H., Wegner, F., Oehlwein, C., Isaias, I. U., Schwarz, J., & Sabri, O. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0979-7 · Cited by 81
Dosimetry in molecular nuclear therapy
Wierts, R., de Pont, C. D. J. M., Brans, B. T., Mottaghy, F. M., & Kemerink, G. J. (2011) · Methods · doi:10.1016/j.ymeth.2011.09.016 · Cited by 22
Cited by
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Somatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274
Del Prete, M., Buteau, F.-A., Arsenault, F., Saighi, N., Bouchard, L.-O., Beaulieu, A., & Beauregard, J.-M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4209-7 · Cited by 184
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1685381 · Cited by 135
Baum, R. P., Zhang, J., Schuchardt, C., Müller, D., & Mäcke, H. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258889 · Cited by 127
Metadata
- Authors
- Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., & Weber, W. A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2014-06-24
- Volume
- 55
- Issue
- 8
- Pages
- 1248-1252
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2171738049
- Cited by
- 266
- References
- 9
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. https://app.cochat.ai/papers/10.2967/jnumed.114.138834
- The paper
- Wild, D., Fani, M., Fischer, R., Del Pozzo, L., Kaul, F., Krebs, S., Fischer, R., Rivier, J. E. F., Reubi, J. C., Maecke, H. R., & Weber, W. A. (2014). Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.114.138834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
